A carregar...
Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
Rivastigmine (or Exelon) is a cholinesterase inhibitor, currently used as a symptomatic treatment for mild-to-moderate Alzheimer’s disease (AD). Amyloid-β peptide (Aβ) generated from its precursor protein (APP) by β-secretase (or BACE1) and γ-secretase endoproteolysis. Alternative APP cleavage by α-...
Na minha lista:
| Publicado no: | Transl Psychiatry |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7026402/ https://ncbi.nlm.nih.gov/pubmed/32066688 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41398-020-0709-x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|